Overview

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

Status:
RECRUITING

Trial end date:
2028-12-01

Target enrollment:

Participant gender:

Summary

The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting.

Phase:

PHASE4

Details

Lead Sponsor:

Swedish Orphan Biovitrum

Collaborator:

PSI CRO